Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertize in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment, further demonstrating its philosophy that investments in companies should positively impact the health and wellbeing of patients. It currently manages over €1.8 bn across nine closed-end funds.
